The Gulf’s GLP-1 boom has yet to move the needle on obesity
Novo Nordisk says demand is rising across the Gulf but there is not enough evidence to prove the drugs are reducing obesity rates, while Eli Lilly says most people who could benefit still do not receive them
We haven't written up this one. Arabian Business has the full story — the link below goes straight to it.